Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
l-epigallocatechin (1 trial)
Atrophy (Phase 3)
Multiple System Atrophy (Phase 3)
Shy-Drager Syndrome (Phase 3)
Trials (1 total)
Trial APIs (1 total)